We are live on !
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter Est. Return
+21.1%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$2.86B
AUM Growth
-$150M
(-5%)
Cap. Flow
-$428M
Cap. Flow % of AUM
Cap. Flow %
-14.96%
Top 10 Holdings %
Top 10 Hldgs %
28.09%
Holding
113
New
30
Increased
18
Reduced
43
Closed
20
Avg Time Held
0.7
years
Top 10 Avg Time Held
0.3
years
Top 20 Avg Time Held
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE HealthCare
GEHC
|
+$83.4M |
| 2 |
AbbVie
ABBV
|
+$76M |
| 3 |
Eli Lilly
LLY
|
+$55.8M |
| 4 |
Pfizer
PFE
|
+$43.5M |
| 5 |
Apellis Pharmaceuticals
APLS
|
+$40.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$72.7M |
| 2 |
Surgery Partners
SGRY
|
+$68.7M |
| 3 |
Akero Therapeutics
AKRO
|
+$65.2M |
| 4 |
Merck
MRK
|
+$63.8M |
| 5 |
Ultragenyx Pharmaceutical
RARE
|
+$56.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.98% |
| 2 | Technology | 0.02% |
| 3 | Miscellaneous | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Denali Therapeutics
DNLI
$2.81B
| $8.34M | 0.29% |
+282,752
| New | +$7.95M |
2023 Q2
0 quarters
|
|
77
Collegium Pharmaceutical
COLL
$755M
| $7.61M | 0.27% |
354,100
-31,400
| -8% | -$713K |
2022 Q4
2 quarters
|
|
78
Alphatec Holdings
ATEC
$1.62B
| $7.07M | 0.25% |
+393,000
| New | +$6.12M |
2023 Q2
0 quarters
|
|
79
AN2 Therapeutics
ANTX
$128M
| $5.59M | 0.2% |
657,200
-66,000
| -9% | -$475K |
2022 Q1
5 quarters
|
|
80
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $5.39M | 0.19% |
+2,765,500
| New | +$6.48M |
2023 Q2
0 quarters
|
|
81
Compass Therapeutics
CMPX
$155M
| $5.15M | 0.18% |
1,620,200
-204,800
| -11% | -$643K |
2021 Q4
6 quarters
|
|
82
SCYNEXIS
SCYX
$36.5M
| $5.13M | 0.18% |
+217,342
| New | +$5.08M |
2023 Q2
0 quarters
|
|
83
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $4.61M | 0.16% |
1,464,034
+559,404
| +62% | +$1.8M |
2022 Q3
3 quarters
|
|
84
Altimmune
ALT
$428M
| $4.14M | 0.14% |
1,174,100
-141,100
| -11% | -$633K |
2021 Q3
7 quarters
|
|
85
Century Therapeutics
IPSC
$248M
| $3.51M | 0.12% |
1,110,900
-157,200
| -12% | -$507K |
2021 Q2
8 quarters
|
|
86
Hyperfine
HYPR
$80M
| $2.55M | 0.09% |
1,188,178
-315,576
| -21% | -$514K |
2021 Q4
6 quarters
|
|
87
DELISTED
Simulations Plus
SLP
| $1.99M | 0.07% |
+45,900
| New | +$2.01M |
2023 Q2
0 quarters
|
|
88
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $1.98M | 0.07% |
21,200
-3,978
| -16% | -$351K |
2021 Q2
8 quarters
|
|
89
Bausch Health
BHC
$2.36B
| $1.72M | 0.06% |
+215,100
| New | +$1.59M |
2023 Q2
0 quarters
|
|
90
Structure Therapeutics
GPCR
$1.5B
| $1.57M | 0.05% |
+37,800
| New | +$1.06M |
2023 Q2
0 quarters
|
|
|
EXAI
91
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $755K | 0.03% |
+127,600
| New | +$782K |
2023 Q2
0 quarters
|
|
92
Arteris
AIP
$922M
| $515K | 0.02% |
+75,500
| New | +$408K |
2023 Q2
0 quarters
|
|
93
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
| $15K | ﹤0.01% |
90,560
-9,439
| -9% | -$1.47K |
2021 Q1
9 quarters
|
|
94
Abbott
ABT
$181B
| – | – |
-354,000
| Closed | -$35.8M | – |
|
95
Arcutis Biotherapeutics
ARQT
$3.62B
| – | – |
-1,628,500
| Closed | -$17.9M | – |
|
96
Avantor
AVTR
$11.1B
| – | – |
-1,125,000
| Closed | -$23.8M | – |
|
97
BridgeBio Pharma
BBIO
$13B
| – | – |
-1,000,000
| Closed | -$16.6M | – |
|
98
DELISTED
BIOATLA INC
BCAB
| – | – |
-12,050
| Closed | -$1.61M | – |
|
99
BioMarin Pharmaceuticals
BMRN
$10.6B
| – | – |
-300,575
| Closed | -$29.2M | – |
|
100
Cytokinetics
CYTK
$8.61B
| – | – |
-252,000
| Closed | -$8.87M | – |
|
Similar funds
ANB
RIP
TAM
B
PWS
LWP
FGA
BVC
Avidity Partners Management's Q2 2023 Portfolio in Review
As of Q2 2023, Avidity Partners Management held 113 positions worth $2.86B, down 5% from $3.01B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Avidity Partners Management withdrew a net $428M in Q2 2023, closing 20 positions and reducing 43 holdings. Its most notable exit was Merck, an estimated $63.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Miscellaneous.
Against the trend, Avidity Partners Management opened a new position in GE HealthCare worth $84.9M.
- Avidity Partners Management's largest Q2 2023 buy was GE HealthCare: 1,045,400 shares worth $84.9M.
- Avidity Partners Management added most to Cencora in Q2 2023, an estimated $30M increase.
- Avidity Partners Management's biggest Q2 2023 reduction was Regeneron Pharmaceuticals, cutting an estimated $72.7M.
- Avidity Partners Management fully exited Merck in Q2 2023, selling an estimated $63.8M.
- Avidity Partners Management's ten largest holdings make up 28% of its $2.86B portfolio in Q2 2023.
- Avidity Partners Management opened 30 new positions and closed 20 in Q2 2023.
- Avidity Partners Management's portfolio value fell 5% quarter-over-quarter to $2.86B.
Based on Avidity Partners Management's 13F filing for Q2 2023, filed 14 Aug 2023.